Thousand Oaks Biopharmaceuticals, an integrated global chemistry, manufacturing and controls (CMC) organization including GMP cell culture media and biomanufacturing capabilities, has closed a $45 million Series A financing round to advance its phase II contract development and manufacturing organization (CDMO) operations; at the same it has started construction of its large-scale cell culture media (LSCCM) cGMP manufacturing facilities based in Haimen, Nantong, a part of greater Shanghai, China...